×
TuHURA Biosciences Net Profit Margin 2010-2024 | HURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
TuHURA Biosciences net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
TuHURA Biosciences Net Profit Margin 2010-2024 | HURA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
TuHURA Biosciences net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$171.8B
Vertex Pharmaceuticals (VRTX)
$122.6B
Gilead Sciences (GILD)
$109.8B
Bristol Myers Squibb (BMY)
$107B
Regeneron Pharmaceuticals (REGN)
$106.1B
CSL (CSLLY)
$96.1B
GSK (GSK)
$78.8B
Alnylam Pharmaceuticals (ALNY)
$38.1B
Argenex SE (ARGX)
$34B
Biogen (BIIB)
$27.1B
BioNTech SE (BNTX)
$26.4B
Illumina (ILMN)
$22.9B
BeiGene (BGNE)
$21.5B
Moderna (MRNA)
$20.5B
Genmab (GMAB)
$15.1B
BioMarin Pharmaceutical (BMRN)
$13.4B
Exact Sciences (EXAS)
$13B
Insmed (INSM)
$12.7B
Incyte (INCY)
$12.6B
Vaxcyte (PCVX)
$12.6B
Sarepta Therapeutics (SRPT)
$12.2B
Bio-Techne Corp (TECH)
$11.1B
QIAGEN (QGEN)
$9.6B
Bio-Rad Laboratories (BIO.B)
$9.3B
Roivant Sciences (ROIV)
$8.7B
Exelixis (EXEL)
$8.2B
Legend Biotech (LEGN)
$8.2B
Intra-Cellular Therapies (ITCI)
$8.1B
Repligen (RGEN)
$8.1B
Revolution Medicines (RVMD)
$7.9B